Fig. 5: SSP classifications for Subtype and ROR risk category in early-stage breast cancer and cross-comparison with administered systemic treatment. | npj Breast Cancer

Fig. 5: SSP classifications for Subtype and ROR risk category in early-stage breast cancer and cross-comparison with administered systemic treatment.

From: RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer

Fig. 5: SSP classifications for Subtype and ROR risk category in early-stage breast cancer and cross-comparison with administered systemic treatment.

The basis for comparisons is the 6660-patient follow-up cohort (Table 1). Summarized proportions are shown on the right side of bar graphs. The first and last year of enrollment (2010 and 2018) are not full calendar years and therefore include notably smaller numbers of enrolled patients. a Proportions of SSP-Subtype by year of diagnosis. b Proportions of SSP-ROR risk category by year of diagnosis. c Proportions for adjuvant treatment within ER+/HER2-/N0 patients diagnosed at age >50 years by different age at diagnosis. Endo: endocrine therapy only, ChemoEndo: adjuvant chemotherapy and endocrine therapy. None: no adjuvant systemic therapy. d Proportions for adjuvant treatment within ER+/HER2-/N0 patients diagnosed at age >50 ≤ 70 years by year of diagnosis. e Cross-comparison of the naive SSP ETR dichotomized for chemotherapy (yes/no) with records of administered systemic treatment within ER+/HER2-/N0 patients at age >50 ≤ 70. The groups for which SSP treatment recommendation is in agreement with the administered treatment are shown in black for regimen without chemotherapy (No CT) and in red for regimen including chemotherapy (CT). The discordant groups where SSP would lead to escalation of treatment (No CT to CT) are shown in orange and de-escalation of treatment (CT to No CT) in blue. f Kaplan-Meier plot for SSP stratification by SSP-ETR treatment recommendation within the N0 subgroup of ER + /HER2- patients diagnosed at age >50 ≤ 70 and no adjuvant treatment. g Kaplan-Meier plot for SSP stratification by SSP-ETR dichotomized for chemotherapy (chemotherapy vs. no chemotherapy) within ER+/HER2-/N0 patients diagnosed at age >50 ≤ 70 treated with adjuvant endocrine therapy only. h Forest plots of Hazard ratios and 95% confidence interval ranges from univariable and i multivariable Cox regression using DRFi as endpoint stratified using SSP treatment recommendation. Multivariable analysis is with tumor size, age at diagnosis, and NHG as covariates. Test (SSP stratification) and subgroup (administered treatment) is specified on the left of the univariable forest plot. Error bars correspond to 95% confidence interval.

Back to article page